title: Effectiveness and safety of bolus administration of alteplase in massive pulmonary embolism.
abstract: Animal studies have demonstrated that thrombolysis with recombinant tissue-type plasminogen activator (rt-PA) is accelerated and that bleeding is reduced when rt-PA is infused over a short period. Previous clinical studies in patients with venous thromboembolism have shown that rt-PA is an effective thrombolytic agent when administered by continuous infusion over 2 to 24 hours. Clinical experience of bolus rt-PA administration in patients with massive acute pulmonary embolism (PE) is, however, limited. A prospective open study was conducted in which 54 patients with massive PE (Miller index > or = 20 of 34) received a 10-minute infusion of rt-PA at a dose of 1 mg/kg. Perfusion lung scanning was used to assess the change in pulmonary perfusion after drug administration. At 48 hours and 10 days, the mean absolute improvements in the perfusion defect were 11 and 31%, respectively. In addition, a significant clinical improvement occurred within 2 hours in 11 of the 15 shocked patients. Five patients died (9%) as a result of persistent shock (3 patients), neurologic damage (1 patient) or intracranial bleeding (1 patient). Major bleeding occurred in 8 patients (15%). Long-term follow-up information was available for 44 of the 49 discharged patients: 2 had died and 12 (27%) complained of persistent exertional dyspnea, 7 of whom had an associated heart or lung disease or chronic thromboembolism at admission. These results suggest that a bolus regimen of rt-PA could provide a convenient approach to thrombolytic therapy in patients with massive PE.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Service de Pneumologie et Réanimation, Hôpital Laënnec, Paris, France.
authors.forename: J L
authors.initials: JL
authors.lastname: Diehl
authors.forename: G
authors.initials: G
authors.lastname: Meyer
authors.forename: J
authors.initials: J
authors.lastname: Igual
authors.forename: M A
authors.initials: MA
authors.lastname: Collignon
authors.forename: M
authors.initials: M
authors.lastname: Giselbrecht
authors.forename: P
authors.initials: P
authors.lastname: Even
authors.forename: H
authors.initials: H
authors.lastname: Sors
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000792:Angiography; D002908:Chronic Disease; D005260:Female; D005500:Follow-Up Studies; D006470:Hemorrhage / Q000503:physiopathology; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D011446:Prospective Studies; D011655:Pulmonary Embolism / Q000000981:diagnostic imaging / Q000188:drug therapy*; D011877:Radionuclide Imaging; D012008:Recurrence; D012449:Safety; D012770:Shock, Cardiogenic / Q000503:physiopathology; D015996:Survival Rate; D013923:Thromboembolism / Q000503:physiopathology; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D006493:Heparin; D010959:Tissue Plasminogen Activator